Introduction
Papillary serous carcinoma of the peritoneum (PSCP) arises from the peritoneal surfaces of the abdomen and pelvis, and occurs exclusively in females. Histologically the disease is identical to papillary serous carcinoma of the ovary (PSOC); however, there is no evidence of a primary ovarian site, and involvement of the ovary is minimal. Both diseases are treated with surgery and chemotherapy, and the CA-125 marker is used to follow the response to treatment. The prognosis of PSCP compared with ovarian carcinoma of the same stage is controversial. Studies report better, worse or equivalent survival rates in PSCP (Altaris et al., 1991; Dalrymple et al., 1989; Truong et al., 1990) .
The clinical similarities and dierences between PSCP and ovarian cancer have stimulated investigations aimed at comparing the molecular genetics of these diseases. One recent study showed overexpression of the HER-2/neu oncogene in 59% of primary peritoneal cancers as compared to 36% of matched ovarian cancers (Kowalski et al., 1997) . The same study reported equal rates of overexpression of the p53 tumor suppressor gene in these tumors. A paper from our laboratory reports variable allelic loss patterns within PSCP cases consistent with a multifocal origin of disease (Muto et al., 1995) .
In this study we choose to focus on genetic events occurring on chromosome 17; a chromosome which has ®gured prominently in the study of the genetic basis of ovarian carcinoma. For example, the p53 gene on the short arm of chromosome 17, is mutated in 44% of ovarian cancers (Greenblatt et al., 1994) . Furthermore, BRCA1, the breast ovarian cancer gene is located on the long arm of chromosome 17, and is implicated in the majority of families with an autosomal dominant pattern of breast and ovarian cancer heredity (Easton et al., 1993; Narod et al., 1995) . Throughout chromosome 17, other areas of frequent genetic deletions have been identi®ed in ovarian cancer suggesting that multiple tumor suppressor genes may reside on this chromosome (Eccles et al., 1990 (Eccles et al., , 1992 Lee et al., 1990; Sato et al., 1991) . Here we report screening of 10 loci spanning chromosome 17 for loss of heterozygosity (LOH) in PSCP, and compare our results to papillary serous carcinoma of the ovary. Due to the evidence noted above that PSCP has a multifocal origin, we evaluated multiple tumor sites for each case tested.
Results
Eleven cases of PSCP were screened. Every patient in the study had stage III ± IV disease with grade 2 ± 3 histology based on criteria of the International Federation of Gynecology and Obstetrics. Family histories of patients were obtained: by patient report, cases 1 and 2 each had one ®rst degree relative with ovarian cancer, case 7 had several relatives with ovarian cancer, PSCP and breast cancer, and case 4 is notable for a personal history of breast cancer.
For each case of PSCP, 1 ± 11 tumor sites were screened using 10 primers spanning chromosome 17 as shown in Table 1 . All cases exhibited LOH at one or more loci tested. Furthermore, at every locus 40 ± 100% of informative cases demonstrated LOH at one or more sites (Figure 1 ). Of note, 75% of informative cases exhibited LOH at the p53 locus. One hundred per cent of informative cases demonstrated LOH at D17S1322 (intragenic to BRCA1), D17S1327 (100 kb distal to BRCA1) and MPO.
Comparison to advanced stage papillary serous ovarian carcinoma (stage III or IV) reveals that PSCP has a higher percentage of cases displaying LOH at 9 out of 10 loci tested on chromosome 17 (Table 2 ). This disparity is particularly notable at the D17S1327 locus which exhibits a LOH rate of 100% of informative cases in PSCP compared with 8% in ovarian cancer (Chi square test of statistical signi®cance, P50.025). The MPO locus also exhibits a large dierence; however only two of the PSCP cases were informative at this site. The allelic loss rate per tumor site is also displayed in Table 2 . For example, at the D17S1322 locus 100% informative cases exhibit LOH at 1 or more sites; however, only 31 of 49 informative sites (63%) exhibit allelic loss. On average each informative case exhibited 68% LOH at this locus. At all but one locus, the average per cent of allelic loss per informative PSCP case is closer to the per cent of PSOC informative cases exhibiting allelic loss (Table  2) . Nine out of 11 cases (cases 1, 3, 4, 5, 6, 7, 8, 9 and 11) exhibited dierent genetic events occurring at dierent sites. In cases 1, 5 and 7 alternating allelic loss is identi®ed ± meaning the upper allele is missing in one site and the lower allele is missing at another site ( Figure 2 ). Microsatellite instability is an uncommon event occurring in 2 ± 14% of informative sites in cases 2, 3, 4 and 8.
Discussion
Systematic screening of chromosome 17 loci in PSCP facilitates comparison of genetic events in PSCP and ovarian cancer. Speci®c regions of interest include the p53 locus and the locus intragenic to BRCA1. At the p53 locus we found that 75% of PSCP cases exhibited allelic loss. This high rate of LOH suggests that the p53 gene may play a role as a tumor suppressor in PSCP as well as sporadic ovarian cancer and many other cancers studied (Greenblatt et al., 1994) .
Analysis of the BRCA1 region revealed that 100% of PSCP cases exhibited allelic loss at the BRCA1 locus (D17S1322), and at the locus 100 kb distal to BRCA1 (D17S1327). There are at least three possible explanations for the high rate of allelic loss in this region. (1) Inherited germline mutations in the BRCA1 gene may be the underlying cause of PSCP in some patients. The histories of four out of 11 patients are notable for at least one ®rst degree relative with ovarian cancer or a personal history of breast cancer suggesting that these patients may have inherited an autosomal dominant gene responsible for the breast ovarian cancer syndrome. These familial cases, coupled with case reports of women developing PSCP following prophylactic oophorectomy (Chen et al., 1985; Lynch et al., 1986; Piver et al., 1993; Tobacman et al., 1982) , reinforce the theory that certain cases of PSCP may be a part of the familial breast ovarian cancer syndrome. (2) Some cases of PSCP may be related to acquired BRCA1 gene mutations. However, it has been shown that BRCA1 mutations are infrequent in sporadic ovarian cancer patients (Takahashi et al., 1995) , suggesting that spontaneous mutations in this gene rarely occur. (3) Alternatively, other genes or regulatory regions¯anking BRCA1 may be involved in the development or progression of PSCP.
Although our data suggest genetic events involving chromosome 17 occur in PSCP as well as papillary serous ovarian carcinoma, there are also two major dierences between the genetic patterns of these diseases. First, the rate of allelic loss in PSCP at several loci tested on chromosome 17 is higher than that seen in stage III or IV PSOC (Table 2) . Although this dierence is statistically signi®cant only at the D17S1327 locus, the consistently higher LOH rate in Table 2 Comparison of LOH on chromosome 17 in informative cases of PSCP and papillary serous ovarian carcinoma (Wertheim et al., 1996) . Column 1: LOH in informative cases of PSCP. PSCP suggests a pattern which might be con®rmed with a larger number of cases. However, according to the multifocality model, each tumor site is a separately arising peritoneal cancer; it is therefore logical to calculate LOH rates based on the number of informative tumor sites, rather than informative cases. The LOH rates per tumor site are generally closer in value to the PSOC rates (Table 2) . For example, 100% of informative PSCP cases exhibit LOH at one or more sites at the D17S1322 locus. The average per cent of sites per case exhibiting allelic loss is 68% compared with 52% of PSOC informative cases exhibiting allelic loss. The converging LOH pro®le lends credence to the concept that PSCP is a multifocal counterpart of epithelial ovarian cancer.
The second characteristic of PSCP which diers from ovarian carcinoma is the high frequency of cases which exhibit dierent genetic events at dierent tumor sites (observed in nine out of 11 cases in our study). This contrasts with studies of ovarian carcinoma showing identical genetic patterns at dierent sites (Jacobs et al., 1992; Li et al., 1993; Mok et al., 1992; Tsao et al., 1993) . Furthermore, alternating allelic loss was identi®ed in three PSCP cases implying that the paternal allele is lost at one site, and the maternal allele is lost at another site. This is clear evidence that the genetic events are site-speci®c. This pattern further con®rms that PSCP has a multifocal origin, as suggested in a previous study (Muto et al., 1995) . Because ovarian carcinoma does not display sitespeci®c mutations, investigators have concluded that ovarian cancer has a unifocal origin.
In conclusion, chromosome 17, with p53 on 17p and BRCA1 on 17q, is of interest in both PSCP and ovarian carcinoma. Further study of a larger series of PSCP cases matched with sporadic and familial ovarian cancer cases would help us understand the origin of these cancers, as well as their similarities and dierences.
Materials and methods

Specimen identi®cation and DNA extraction
Archival pathology specimens were reviewed and 11 cases meeting the International Federation of Gynecology and Obstetrics criteria for PSCP were identi®ed. In each case, the ovaries were normal-sized and either completely uninvolved or contained only small capsular implants without stromal disease. For each case we identi®ed 1 ± 11 tumor sites in addition to normal tissue from uninvolved areas such as the cervix. A pathologist reviewed hematoxylin-eosin stained sections, and on corresponding blocks of paran-embedded tissue circled areas where at least 80% of cells appeared cancerous. The area surrounding the tumor was trimmed, then the tumor was shredded using a microtome. DNA was obtained via two phenol-chloroform extractions followed by DNA precipitation.
Tandem repeat polymorphism analysis
Loss of heterozygosity and microsatellite instability were studied using PCR ampli®cation of chromosome 17 alleles anked by CA-repeat regions. Ten DNA primers spanning chromosome 17 with high rates of heterozygosity were purchased from Research Genetics (Huntsville, Alabama). These include p53 (17p13.1), D17S261 (17p11.2-12), CHRNB1 (17p11-12), D17S250 (17q11.2-12), THRA1 (17q11.2-12), D17S1322 (17q21), D17S1327 (17q21), MFD188 (17q21), and .
Primers were labeled with 32 P-ATP using T4 polynucleotide kinase (Promega Corporation, Madison, Wisconsin). Standard PCR conditions involved 30 ± 35 cycles of 948C for 1 min, 45 ± 608C for 30 s, 728C for 1 min. The PCR product was diluted with 45 ml EDTA-formamide dye, denatured, and run on a preheated 6% polyacrylamide gel at 1700 volts. The gel was then dried and exposed to X-ray ®lm for 1 ± 24 h. The banding patterns were visually evaluated. When normal tissue produced heterozygous bands, allelic loss was interpreted if a tumor allele was 75% lighter than its pair. Microsatellite instability was de®ned as a frameshift of one or two tumor bands compared with normal bands. All cases of MI were con®rmed by rerunning the PCR product on a gel to exclude possible gel irregularity causing a false shift.
The rates of allelic loss at dierent loci in PSCP and advanced stage papillary serous ovarian carcinoma were compared. The Chi squared test was used for statistical analysis, and P50.05 was considered statistically signi®cant.
